The Therapeutic Landscape of Salivary Gland Malignancies-Where Are We Now?

ABSTRACT: Salivary gland malignancies (SGMs) account for less than 5% of new diagnoses in head and neck tumors. If feasible, surgery is the preferred treatment modality. Nevertheless, some malignancies have a tendency of recurrence, with possible distant metastasis. Alternative treatment strategies, such as primary radiation or chemotherapeutics, often present low response rates. As a result, there is an unmet need for novel therapeutic approaches. Nowadays, target-based therapies (e.g., small inhibitors and immunotherapy) are used by the medical oncologist for possible treatment of advanced SGMs. Based on recent published trials, some novel treatments may provide additional disease control for some patients. However, sample sizes are small, the general findings are unsatisfactory, and a lot of unce

SUBMITTER: Cleymaet R 

PROVIDER: S-EPMC9740091 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature